Freeline Therapeutics Holdings PLC ADR (FRLN): Price and Financial Metrics
FRLN Price/Volume Stats
| Current price | $6.48 | 52-week high | $8.74 |
| Prev. close | $6.48 | 52-week low | $2.11 |
| Day low | $6.48 | Volume | 5,600 |
| Day high | $6.49 | Avg. volume | 12,055 |
| 50-day MA | $6.40 | Dividend yield | N/A |
| 200-day MA | $4.58 | Market Cap | 28.13M |
FRLN Stock Price Chart Interactive Chart >
Freeline Therapeutics Holdings PLC ADR (FRLN) Company Bio
Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. It develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Nathwani on April 3, 2020 and is headquartered in Stevenage, the United Kingdom.
Latest FRLN News From Around the Web
Below are the latest news stories about FREELINE THERAPEUTICS HOLDINGS PLC that investors may wish to consider to help them evaluate FRLN as an investment opportunity.
Freeline (FRLN) Shares Rise on Merger Agreement With SynconaFreeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise. |
Syncona to Acquire Freeline TherapeuticsFreeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support ongoing adva |
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressSubstantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in plasma GCase activity and normalization of cellular GCase levels continue to be observed in first two patients treated with FLT201 FLT201 continues to be well-tolerated, with no serious adverse events Third patient dosed this month in ongoing Phase 1/2 GALILEO-1 trial LONDON, Oct. 25, 2023 (GLOBE NEWSWIR |
Here's Why We're A Bit Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressLONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate, in patients with Gaucher disease Type 1 at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress being held October 24-27, 2023 in Brussels, Belgium. The oral presentation will include data on safety, tolerability, GCase en |
FRLN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 72.80% |
| 3-year | -89.23% |
| 5-year | N/A |
| YTD | 1.73% |
| 2023 | -10.62% |
| 2022 | -76.01% |
| 2021 | -89.16% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...